Journal: International journal of biological sciences

Article Title: FGF7 and FGF10 Promote Fate Transition of Human Epidermal Cell-derived Organoids to an Eccrine Gland Phenotype.

doi: 10.7150/ijbs.97422

Figure Lengend Snippet: Figure 6. Addition of inhibitors targeting MEK1/2 impairs reconstitution of FDKCs into ESG-characterized organoids. (A) Phase-contrast images show the morphology of 3D organoids constructed by "FDKCs + Matrigel" in the presence of FGF7 and FGF10 with or without the MEK1/2 inhibitor U0126 addition at day 9 of culture. (B) RT-qPCR detection of transcriptional expression levels of ERK1/2, FGFR1, FGFR2, K7, and K73 in FGF-fed organoids with (+) or without (-) the addition of the MEK1/2 inhibitor U0126. (C, D) Protein expression of ERK1/2, p-ERK1/2, FGFR1, FGFR2, K7, and K73 in FGF- fed organoids with (+) or without (-) the addition of the MEK1/2 inhibitor U0126. GAPDH serves as the internal control. (C) WB assay. (D) The relative integrated density of ERK1/2, p-ERK1/2, FGFR1, FGFR2, K7, and K73 in accordance with (C). The asterisk (*) indicate significant differences at p < 0.05, and the asterisks (**) indicate significant differences at p < 0.001 (one-way ANOVA, t test).

Article Snippet: For the pathway interference assay experiment, 40 μM MEK1/2 specific inhibitor U0126 (S1901, Beyotime, Shanghai, China), 50 μM FGFR1 inhibitor PD166866 (S8493; Selleck,) and 50 μM FGFR2 inhibitor Formononetin (HY-N0183; MCE) were added to KSFM complete medium in the presence or absence of human FGF7 and FGF10, respectively.

Techniques: Construct, Quantitative RT-PCR, Expressing, Control